research Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody–drug conjugate in breast cancer
Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
Search
for
Sort by
Research
630-660 / 1000+ results 
research Case Report: Postmenopausal hyperandrogenism misled by adrenal incidentaloma: a rare case of androgen-secreting ovarian adult granulosa cell tumor and clinical implications
Thorough evaluation and surgery are crucial for managing rare ovarian tumors in postmenopausal women with high androgen levels.
research Safety and efficacy of low-dose metronomic cyclophosphamide plus vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.
The treatment is safe and shows promise for metastatic breast cancer.
research Table_1.docx
Androgen suppression therapy (AST) doesn't significantly lower bladder cancer risk, but using finasteride, a type of AST, might reduce it. AST decreases recurrence-free survival but doesn't affect overall survival or progression-free survival. More research is needed to understand AST's benefits.
research Dutasteride improves hair growth in patients with male pattern baldness more effectively than finasteride,
Dutasteride is more effective for male pattern baldness than finasteride, and black cohosh extract BNO 1055 is as effective as conjugated estrogens in treating postmenopausal symptoms, with added benefits in reducing sweating and mental symptoms.
research Moving Chemoprevention Forward into the Most Promising Areas of Study
Further research is needed to develop effective cancer prevention strategies.
research Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study
Men taking dutasteride may have a higher risk of age-related macular degeneration.
research Prostatakarzinom
5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
research Mitoxantrone
Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
research Advances in the Treatment of Androgenetic Alopecia: A Review of Mechanisms and the Clinical Efficacy of Combination Drug Therapy
Combination drug therapy improves hair growth and patient care for androgenetic alopecia.
research Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.
research Endocrinological evaluation and hormonal therapy for women with difficult acne
Hormonal therapy is a good option for women with severe acne, especially when there's a chance of hormone imbalance.
research Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents
Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.
research Moderne Untersuchungsmethoden zur Evaluation von Haarausfall und Alopezie bei Frauen
Chemotherapy causes temporary hair loss in women, while Tamoxifen does not significantly affect hair, and genetics show no link between female pattern hair loss and common baldness genes.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Progestogens with Antiandrogenic Properties
research MP-09.08
The study found that different criteria led to different patient groups in the CombAT study compared to the MTOPS study.
research Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report
Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
research The Antiandrogens
research NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
research COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
research Finasteride/testosterone undecanoate
Testosterone undecanoate caused hair loss; finasteride improved it but caused stomach issues for one patient.
research Bilateral ovarian steroid cell tumor in a postmenopausal woman with progressive hyperandrogenism
Surgery removed ovarian tumors, normalizing testosterone and improving symptoms.
research Topic use of dutasteride for treatment of androgenic alopecia in male and female: A controlled pilot study
Dutasteride can help treat hair loss in both men and women.
research Testosterone Therapy in Premenopausal Women
Testosterone therapy may improve mood, well-being, and sexual function in premenopausal women, but more research is needed on its long-term safety and effectiveness.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research A Randomized Double-Blind Placebo-Controlled Pilot Trial on the Effects of Testosterone Undecanoate Plus Dutasteride or Placebo on Muscle Strength, Body Composition, and Metabolic Profile in Transmen
Testosterone with dutasteride improves muscle strength and body composition in trans men.
research Bicalutamide
research 5116 Postmenopausal Hyperandrogenism due to Rare Ovarian Tumor
Rare ovarian tumors can cause hyperandrogenism, even if imaging appears normal.
research Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α.
The treatment was not recommended due to limited effectiveness and significant side effects.